NovaRay Announces Opening of New and Expanded Facility
NEWARK, California, June 17, 2008 –
NovaRay, Inc. (NovaRay), a
developer of unique digital cardiac x-ray imaging technology and the ScanCath™
cardiac catheterization system that provides advanced imaging capabilities
coupled with reductions in radiation, is pleased to announce the opening of its
new headquarters in Newark, California. NovaRay’s new facility, located at 39655
Eureka Drive, Newark, California, has over 41,000 square feet of manufacturing
and development space to support the ScanCath™ product introduction.
“We are very excited about our new facility. The space is of a sufficient size
and structure to support our growth and development as we scale-up and roll-out
with the development of our first clinical product, the ScanCath™ cardiac
catheterization system,” said Jack Price, NovaRay’s CEO and President.
“Our new location will not only provide us with an environment for our own
development and growth, but it will also house our development partner, Triple
Ring Technologies, Inc.,” commented Marc Whyte, NovaRay’s COO.
In addition to the new headquarters based in Newark, California, NovaRay has
also opened a marketing and sales office based in Bellevue, Washington.
About NovaRay Medical, Inc.
NovaRay is a medical imaging company focused on developing
unique innovations in proprietary digital cardiac x-ray
technology. NovaRay’s initial clinical offering, the
ScanCath™ cardiac catheterization system, offers advanced,
revolutionary, and breakthrough imaging capabilities,
coupled with dramatic reductions in radiation exposure to
patients, operators, and staff.
About Triple Ring Technologies
Triple Ring Technologies, headquartered in Newark, CA, is an
innovative research and development company that partners
with clients to deliver complex technical solutions. Founded
in 2004, Triple Ring’s team of scientists and engineers
provides leading edge, integrated technical design,
engineering, and business services. Clients include
entrepreneurs, established companies, and investors in the
medical device, life sciences, optics, clean technology, and
digital imaging fields.
--- Forward Looking Statements ---
This press release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. Such forward-looking statements
include, but are not limited to, statements relating to the
new facility being of a sufficient size and structure to
support growth, and the development of NovaRay’s first
clinical product. These forward-looking statements involve
important factors that could cause our actual results to
differ materially from those in such forward-looking
statements.
Such important factors involve risks and uncertainties,
including, but not limited to, the possibility that NovaRay
may not be able to secure additional funding, the
possibility that NovaRay may not be able to produce and
market successfully any of its products, the possibility
that NovaRay’s products will not be sufficiently accepted by
physicians, hospitals and other potential customers, the
possibility that NovaRay will not obtain or maintain
necessary regulatory clearances or approvals relating to
NovaRay’s products, and other factors, including those
factors described in the Forms 10-KSB and S-1 for NovaRay
Medical, Inc., NovaRay’s parent corporation, and other
filings NovaRay Medical, Inc. filed with the Securities and
Exchange Commission.
Any forward-looking statements contained in this press
release speak only as of the date hereof, and NovaRay does
not undertake any obligation to update any forward-looking
statement to reflect events or circumstances after the date
of this press release.
For more information, contact:
Gurinder Parhar
Rohini Hira
Triple Ring Technologies, Inc.
NovaRay, Inc.
gparhar@tripleringtech.com
rhira@novaraymedical.com
(510) 592-3000 ext. 108
(510) 619-9200 ext. 111
www.tripleringtech.com
www.novaraymedical.com
